Duc Tran has joined ArisGen as Preclinical & PhI...
NEWS & EVENTS
Campus Biotech - Geneva,...
Dr Paolo Botti (CSO) will be attending the Peptide...
Andrew Parker (CEO) will be attending Bio-Europe 2014 in...
Paolo Botti (CSO) will be attending the 29 éme...
The 2014 BIO International Convention is June 23-26 at...
Dr Paolo Botti (CSO) will be attending the 14th Naples...
Andrew Parker, CEO and Paolo Botti, CSO will be...
Dr Paolo Botti (CSO) will be attending the IBC's 6th...
Arisgen is a drug delivery company with a proprietary formulation technology called ArisCrown that has the potential to transform the injectable peptide drug market offering oral alternatives for these medications.
Arisgen is developing its own products focused on the treatment of metabolic diseases and oncology and actively seeking partners for the technology.